From: Clinical course and significance of nontuberculous mycobacteria and its subtypes in cystic fibrosis
Patients with Slow-growing NTM (N = 17) | Patients with Rapidly Growing NTM (N = 8) | ||||
---|---|---|---|---|---|
N | N (%) | N | N (%) | P-value | |
Common bacterial colonization at time of positive NTMa | 17 | 8 | |||
P. aeruginosa | 13 (76) | 8 (100) | 0.27 | ||
Methicillin-susceptible S. aureus | 13 (76) | 5 (63) | 0.64 | ||
Methicillin-resistant S. aureus | 6 (35) | 3 (38) | 0.99 | ||
S. maltophilia | 4 (22) | 4 (50) | 0.36 | ||
Escherichia coli | 1 (6) | – | 0.99 | ||
A. baumannii | – | 1 (13) | 0.32 | ||
None | 1 (6) | – | 0.99 | ||
History of ABPAb | |||||
Before NTM infection | 17 | 8 | 0.53 | ||
No | 14 (82) | 8 (100) | |||
Yes | 3 (18) | – | |||
After NTM infection | 17 | 8 | 0.64 | ||
No | 13 (76) | 5 (62) | |||
Yes | 4 (24) | 3 (38) | |||
American Thoracic Society treatment criteria | 16 | 6 | |||
Clinical | 11 (69) | 6 (100) | 0.27 | ||
New changes on chest x-ray or computed tomography | 7 (44) | 3 (50) | 0.99 | ||
Two positive sputum or bronchoalveolar lavage | 11 (69) | 4 (67) | 0.99 | ||
Received treatment for NTM | 16 | 8 | 0.58 | ||
No | 14 (88) | 6 (75) | |||
Yes | 2 (12) | 2 (25) |